Literature review of the sensitivity and specificity of various screening tests for chronic atrophic gastritis, classified by diagnostic method
Reference | Subjects (location) | Screening test | Outcome | Outcome prevalence (%) | Diagnostic methoda | Sensitivity (%) | Specificity (%) |
---|---|---|---|---|---|---|---|
Varis et al. (20) | 159 relatives of patients with | PGI <20 μg/l | Atrophy | 13.4 | NSb | 91.3 | 97.3 |
pernicious | Gastrin >100 ng/l | 82.6 | 97.3 | ||||
(Finland) | PGI <20 μg/l+ gastrin >100 ng/l | 82.6 | 100 | ||||
Samloff et al. | 170 relatives of patients with | PGI <62 μg/l+ PGI/II <4.3 | AG (0)c | 13.5 | NS | 91.3 | 98.6 |
pernicious (Finland) | PGI <62 μg/l+ PGI/II <4.3 | AG | 23.5 | 57.5 | 92.3 | ||
Kekki et al. (10) | 276 relatives of gastric cancer | PGI <25 μg/l | AG (1) | 2.7 | NS | 89.5 | 93.9 |
patients | PGI <30 μg/l | 89.5 | 91.5 | ||||
424 matched controls | Gastrin >200 ng/l | 31.6 | 95.9 | ||||
73 relatives of patients with | Gastrin >100 ng/l | 57.9 | 90.2 | ||||
pernicious anemia | |||||||
(Finland) | |||||||
Guarner et al. | 217 symptomatic patients | H. pylori (serology) | Atrophy | 77.4d | NS | 93.4 | 50 |
(29) | 28 asymptomatic controls | H. pylori (pathology) | 72.7e | 92.3 | 21.1 | ||
(Mexico) | |||||||
Halissey et al. (8) | 432 dyspepsia patients | PGI <20 μg/l | AG, IM, or polyp | 16.1 | NS | 6 | 98.6 |
26 asymptomatic controls | PGI <30 μg/l | 11.9 | 96 | ||||
(United Kingdom) | |||||||
Inoue et al. (7) | 200 endoscopy patients | PGI ≤30 μg/l+ PGI/II <2 | Atrophy | 58.5 | NS | 18.8 | 100 |
(Japan) | PGI ≤70 μg/l+ PGI/II ≤3 | 65 | 92.8 | ||||
PGI ≤40 μg/l+ PGI/II ≤2.5 | 82.1 | 74.7 | |||||
H. pylori (serology) | 85.5 | 37.3 | |||||
Faisal et al. (34) | 125 healthy adults ages ≥65 years (United States) | H. pylori (serology) | AG | 10.4 | PGI/PGII <2.9+ PGI <20 μg/l | 38.5 | 51.1 |
Borch et al. (6) | 179 patients with AG | PGI <71.6 μg/l | Atrophy | 78.2 | Whitehead | 96.6 | 86 |
29 gastric cancer patients | PGI/II <5.5 | Atrophy | 99.4 | 94 | |||
15 gastrectrectomy patients | PGI <71.6 μg/l | AG (0) | 74.6 | 100 | 86 | ||
50 normal controls | PGI/II <5.5 | AG (0) | 99.3 | 94 | |||
(Sweden) | |||||||
Sitas et al. (19) | 87 endoscopy patients | PGI/II <1.5 | AG (2) | 25.3 | Whitehead | 26.7 | 89.1 |
(United Kingdom) | H. pylori (serology) | 86.7 | 78.3 | ||||
H. pylori+ PCI/PCII <1.5 | 26.7 | 95.7 | |||||
Zhang et al. (23) | 2646 healthy adults, ages 35–64 | PGI/II <5 | Atrophy | 8.2 | Chinese | 19.2 | 72.1 |
years | H. pylori (serology) | Assoc. of | 87.5 | 29.7 | |||
(China) | Gastric | ||||||
Cancer | |||||||
Hu et al. (35) | 161 H. pylori-positive non-ulcer dyspepsia patients | Age >40 years | Atrophy | 59.6 | Sydney | 75 | 72.3 |
(China) | |||||||
Kuipers et al. | 58 H. pylori-positive patients with | CagA (overall; serology) | Atrophy | 44.8f | Sydney | 57.7 | 71.9 |
(13) | follow-up | CagA (at baseline) | 24.1g | 57.1 | 63.6 | ||
(the Neterlands) | CagA (at follow-up) | 31.8h | 42.9 | 66.7 | |||
Asaka et al. (36) | 85 healthy adults | H. pylori (serology) | Atrophy | 52.9 | Sydney | 96 | 45 |
(Japan) | |||||||
Knight et al. (11) | 6 workers with PGI <25 μg/l | PGI <25 μg/l | Atrophy | 17.6 | Sydney | 44.4 | 97.6 |
19 workers with PGI >150 μg/l | H. pylori (serology) | 100 | 59.5 | ||||
34 matched controls | PGI <80 μg/l+ H. pylori | 88.9 | 92.3 | ||||
(United Kingdom) | PGI <80 μg/l+ H. pylori+ PGI/II <2.5 | 77.8 | 100 | ||||
Pilotto et al. (15) | 71 endoscopy patients age ≥60 years | CagA (by PCR) | Atrophy | 26.8 | Sydney | 78.9 | 57.7 |
(Italy) |
a Method used to assess atrophy.
b NS, not stated; AG, atrophic gastritis; IM, intestinal metaplasia.
c Atrophic gastritis: 0, severe; 1, severe diffuse; 2, moderate chronic.
d Analysis with serology.
e Analysis with pathology.
f \
N
h Prevalence: overall; at baseline; at follow-up.